Literature DB >> 18024413

The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group.

Martin Stanulla, Christian Dynybil, Dorothee B Bartels, Michael Dördelmann, Lutz Löning, Alexander Claviez, Martin Schrappe.   

Abstract

In a matched-pair study, we analyzed the association of a phenotypically relevant NQO1 polymorphism (C609T) with risk of secondary malignant neoplasms (SMN) after treatment for childhood acute lymphoblastic leukemia. Patients carrying a variant low-activity NQO1 allele had a significantly increased risk of developing a SMN. The observed effect was restricted to solid tumors.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18024413     DOI： 10.3324/haematol.10260

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  7 in total

1.  DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia.

Authors:  Nina Erčulj; Barbara Faganel Kotnik; Maruša Debeljak; Janez Jazbec; Vita Dolžan
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-01       Impact factor: 4.553

2.  Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Authors:  Kjeld Schmiegelow; Ibrahim Al-Modhwahi; Mette Klarskov Andersen; Mikael Behrendtz; Erik Forestier; Henrik Hasle; Mats Heyman; Jon Kristinsson; Jacob Nersting; Randi Nygaard; Anne Louise Svendsen; Kim Vettenranta; Richard Weinshilboum
Journal:  Blood       Date:  2009-02-17       Impact factor: 22.113

3.  Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.

Authors:  Kjeld Schmiegelow; Mette Frandsen Levinsen; Andishe Attarbaschi; Andre Baruchel; Meenakshi Devidas; Gabriele Escherich; Brenda Gibson; Christiane Heydrich; Keizo Horibe; Yasushi Ishida; Der-Cherng Liang; Franco Locatelli; Gérard Michel; Rob Pieters; Caroline Piette; Ching-Hon Pui; Susana Raimondi; Lewis Silverman; Martin Stanulla; Batia Stark; Naomi Winick; Maria Grazia Valsecchi
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

4.  Association of NAD(P)H:quinone oxidoreductase 1 polymorphism and Alzheimer's disease in Chinese.

Authors:  Jian-Tao Bian; Hua-Lu Zhao; Zhen-Xin Zhang; Xiu-Hua Bi; Jun-Wu Zhang
Journal:  J Mol Neurosci       Date:  2008-02-06       Impact factor: 3.444

5.  Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study.

Authors:  Pablo Conesa-Zamora; Javier Ruiz-Cosano; Daniel Torres-Moreno; Ignacio Español; María D Gutiérrez-Meca; Javier Trujillo-Santos; Elena Pérez-Ceballos; Rocío González-Conejero; Javier Corral; Vicente Vicente; Miguel Pérez-Guillermo
Journal:  BMC Cancer       Date:  2013-05-07       Impact factor: 4.430

6.  Interactions between glucocorticoid treatment and cis-regulatory polymorphisms contribute to cellular response phenotypes.

Authors:  Joseph C Maranville; Francesca Luca; Allison L Richards; Xiaoquan Wen; David B Witonsky; Shaneen Baxter; Matthew Stephens; Anna Di Rienzo
Journal:  PLoS Genet       Date:  2011-07-07       Impact factor: 5.917

7.  Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia.

Authors:  J Gregers; H Gréen; I J Christensen; K Dalhoff; H Schroeder; N Carlsen; S Rosthoej; B Lausen; K Schmiegelow; C Peterson
Journal:  Pharmacogenomics J       Date:  2015-01-13       Impact factor: 3.550
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.